Table 1 Descriptive data of multiple myeloma patients (group I)
From: Telomerase reverse transcriptase gene amplification in hematological malignancies
Parameter | MM patients (N = 15) |
|---|---|
Age (mean ± SD) | 68.2 ± 6.8 |
Gender, N (%) | |
Male | 12 (80%) |
Female | 3 (20%) |
Presentation, N (%) | |
DNV | 12 (80%) |
Relapse | 3 (20%) |
Lymphadenopathy, N (%) | 2 (13.3%) |
Splenomegaly, N (%) | 2 (13.3%) |
Hepatomegaly, N (%) | 1 (6.7%) |
WBC count (× 109/l) (mean ± SD) | 9 ± 5.2 |
Hb level (g/dl) (mean ± SD) | 10.5 ± 2.1 |
Platelet count (× 109/l) (mean ± SD) | 146.5 ± 8.5 |
BM plasma cells% (mean ± SD) | 51.6 ± 14 |
Albumin level, N (%) | |
< 3.5 g/dl | 9 (60%) |
≥ 3.5 g/dl | 6 (40%) |
β2 microglobulin | |
< 3.5 mg/l | 5 (33.3%) |
≥ 3.5 mg/l | 10 (66.7%) |
Lactate dehydrogenase (U/L) (mean ± SD) | 286.7 ± 66 |
Corrected calcium | |
< 10.5 mg/dl | 11 (73.3%) |
≥ 10.5 mg/dl | 4 (26.7%) |
Protein electrophoresis, N (%) | |
Monoclonal gammopathy | 6 (40%) |
Hypergammaglobulinemia | 1 (6.7%) |
Hypoalbuminemia | 3 (20%) |
Normal | 5 (33.3%) |
Karyotype, N (%) | |
Normal | 14 (93.3%) |
Numerical aberrations | 1 (6.7%) |
P53 (17p13.1) deletion, N (%) | 4(26.7%) |
14q32 rearrangement, N (%) | 3 (20%) |
13q14.3 deletion, N (%) | 5 (33.3%) |
TERT amplification, N (%) | 3 (20%) |
Prognosis, N (%) | |
I | 6 (40%) |
II | 1 (6.6%) |
III | 8 (53.3%) |